AIIMS Jodhpur · AIIMS/JDH/PED/2026/685
Efficacy and safety of substitution of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced-stage pediatric Hodgkin Lymphoma: A phase II/III, multicentric, open-label, randomized controlled trial 2026
Applications closed closed 10 Sep 2026
All India Institute of Medical Sciences, Jodhpur is recruiting Efficacy and safety of substitution of bleomycin by low dose nivolumba in ABVD (Doxorubicin + Bleomycin + Vinblastine + Dacarbazine) backbone chemotherapy in newly diagnosed advanced-stage pediatric Hodgkin Lymphoma: A phase II/III, multicentric, open-label, randomized controlled trial. Applications opened 02 September and close 10 September 2026. Advertisement AIIMS/JDH/PED/2026/685.
This drive does not publish a state-by-state vacancy table, or we have not been able to read one from it yet — so this page does not show one.
| Applications open | 02 Sep 2026 |
|---|---|
| Last date | 10 Sep 2026 |
| Age | up to 30 years |
| Age reckoned as on | 10 Sep 2026 |
| Qualification | Graduate in Science/relevant subjects from a recognized university/Institution |
| Fee | not read yet |
| Advertisement | AIIMS/JDH/PED/2026/685 |
| Pay | Rs. 20,000/- + 18% HRA (23,600/-) per month |
| Selection | Walk-In-Interview → written examination |
| Documents | Passport-size photograph; essential qualifications certificates; experience certificates; No Objection Certificate |
Blanks are ours, not the document's. Every filled value was read from the notification linked below; anything marked not read yet is a gap in our reading, not a field the recruiter left empty.
1788414536_lymphoma recruitment letter 02 September.pdf
— the official AIIMSJ notification (aiimsj-table).Not checked. No state-by-state table could be read from this document, so there was no arithmetic to reconcile. The dates and identifiers above come from the document itself.
Fetched 13 Oct 2026, 01:10 UTC.